[Congressional Record Volume 172, Number 71 (Wednesday, April 22, 2026)]
[Senate]
[Pages S2003-S2004]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 5194. Mr. MERKLEY submitted an amendment intended to be proposed 
by him to the concurrent resolution S. Con. Res. 33, setting forth the 
congressional budget for the United States Government for fiscal year 
2026 and setting forth the appropriate budgetary levels for fiscal 
years 2027 through 2035; which was ordered to lie on the table; as 
follows:

       At the end of title III, add the following:

[[Page S2004]]

  


     SEC. 3___. DEFICIT-NEUTRAL RESERVE FUND RELATING TO REDUCING 
                   FEDERAL SPENDING FOR PRESCRIPTION DRUGS.

       The Chairman of the Committee on the Budget of the Senate 
     may revise the allocations of a committee or committees, 
     aggregates, and other appropriate levels in this resolution, 
     and make adjustments to the pay-as-you-go ledger, for one or 
     more bills, joint resolutions, amendments, amendments between 
     the Houses, motions, or conference reports relating to 
     reducing health care costs, which may include legislation 
     enabling Americans to have a much improved opportunity to 
     purchase prescription drugs at, or near, the lower prices 
     manufacturers charge in other similarly developed nations, 
     requiring pharmaceutical manufactures to report annually the 
     amount of taxpayer dollars used to benefit manufacturers' 
     research and development efforts, or enacting other 
     mechanisms to purchase prescription drugs at lower prices, by 
     the amounts provided in such legislation for those purposes, 
     provided that such legislation would not increase the deficit 
     over the period of the total of fiscal years 2026 through 
     2035.
                                 ______